Hydrocortisone Butyrate Ointment
NDC Package 68682-271-45
Package Information
Hydrocortisone Butyrate ointment is a medication used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). This formulation utilizes a ointment delivery system. Marketed by Oceanside Pharmaceuticals, this product is identified by NDC 68682-271 and is authorized under FDA application NDA018652.
Identification & Billing
- RxCUI: 1370758 - hydrocortisone butyrate 0.1 % Topical Ointment
- RxCUI: 1370758 - hydrocortisone butyrate 0.001 MG/MG Topical Ointment
- RxCUI: 1370758 - hydrocortisone butyrate 1 MG per GM Topical Ointment
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 68682 - Oceanside Pharmaceuticals
- 68682-271 - Hydrocortisone Butyrate
- 68682-271-45 - 1 TUBE in 1 CARTON / 45 g in 1 TUBE
- 68682-271 - Hydrocortisone Butyrate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (68682-271). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 68682-271-45 identifies a specific commercial package of 1 tube in 1 carton / 45 g in 1 tube of Hydrocortisone Butyrate, a human prescription drug labeled by Oceanside Pharmaceuticals. This ointment is formulated for topical use and contains hydrocortisone butyrate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Oceanside Pharmaceuticals on September 01, 2009. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). Hydrocortisone butyrate reduces the swelling, itching, and redness that can occur in these types of conditions. The topical solution is used to treat severe dandruff (seborrheic dermatitis). This medication is a medium-strength corticosteroid.
How is this Oceanside Pharmaceuticals product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 68682027145. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 45 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.